Information de reference pour ce titreAccession Number: | 00024798-202203000-00009.
|
Author: | Huang, Edmund 1; Maldonado, Angela Q. 2; Kjellman, Christian 2; Jordan, Stanley C. 1
|
Institution: | (1) Department of Medicine Division of Nephrology Transplant Immunotherapy Program Cedars-Sinai Medical Center Los Angeles California USA (2) Hansa Biopharma Lund Sweden
|
Title: | Imlifidase for the treatment of anti-HLA antibody-mediated processes in kidney transplantation.[Review]
|
Source: | American Journal of Transplantation. 22(3):691-697, March 2022.
|
Author Keywords: | alloantibody; clinical research; desensitization; immune modulation; immunosuppressant - other; immunosuppression; kidney transplantation; nephrology; practice; rejection: antibody-mediated (ABMR); sensitization.
|
References: | 1. Stewart DE, Kucheryavaya AY, Klassen DK, Turgeon NA, Formica RN, Aeder MI. Changes in Deceased Donor Kidney Transplantation One Year After KAS Implementation. Am J Transplant. 2016;16:1834-1847. 10.1111/ajt.13770
2. Schinstock CA, Smith BH, Montgomery RA, et al. Managing highly sensitized renal transplant candidates in the era of kidney paired donation and the new kidney allocation system: Is there still a role for desensitization? Clin Transplant. 2019;33:e13751. 10.1111/ctr.13751
3. Maldonado AQ, Sjoholm K, Lee J, Olsson H, Kjellman C, Stewart DE. Identifying sensitized kidney candidates with markedly low access to deceased donor transplantation by granular CPRA and Blood type. OBM Transplant. 2021;5(2):1-14. 10.21926/obm.transplant.2102143
4. Orandi BJ, Luo X, Massie AB, et al. Survival Benefit with Kidney Transplants from HLA-Incompatible Live Donors. N Engl J Med. 2016;374:940-950. 10.1056/NEJMoa1508380
5. Montgomery RA, Lonze BE, King KE, et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011;365:318-326. 10.1056/NEJMoa1012376
6. Brezski RJ, Vafa O, Petrone D, et al. Tumor-associated and microbial proteases compromise host IgG effector functions by a single cleavage proximal to the hinge. Proc Natl Acad Sci U S A. 2009;106:17864-17869. 10.1073/pnas.0904174106
7. von Pawel-Rammingen U, Bjorck L. IdeS and SpeB: immunoglobulin-degrading cysteine proteinases of Streptococcus pyogenes. Curr Opin Microbiol. 2003;6:50-55. 10.1016/S1369-5274(03)00003-1
8. Winstedt L, Jarnum S, Nordahl EA, et al. Complete Removal of Extracellular IgG Antibodies in a Randomized Dose-Escalation Phase I Study with the Bacterial Enzyme IdeS-A Novel Therapeutic Opportunity. PLoS One. 2015;10:e0132011. 10.1371/journal.pone.0132011
9. Jordan SC, Lorant T, Choi J, et al. IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation. N Engl J Med. 2017;377:442-453. 10.1056/NEJMoa1612567
10. Al-Salama ZT. Imlifidase: First Approval. Drugs. 2020;80(17):1859-1864. 10.1007/s40265-020-01418-5
11. Ge S, Chu M, Choi J, et al. Imlifidase inhibits HLA antibody-mediated nk cell activation and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro. Transplantation. 2020;104:1574-1579. 10.1097/TP.0000000000003023
12. Lorant T, Bengtsson M, Eich T, et al. Safety, immunogenicity, pharmacokinetics, and efficacy of degradation of anti-HLA antibodies by IdeS (imlifidase) in chronic kidney disease patients. Am J Transplant. 2018;18:2752-2762. 10.1111/ajt.14733
13. Jarnum S, Bockermann R, Runstrom A, Winstedt L, Kjellman C. The Bacterial Enzyme IdeS Cleaves the IgG-Type of B Cell Receptor (BCR), Abolishes BCR-Mediated Cell Signaling, and Inhibits Memory B Cell Activation. J Immunol. 2015;195:5592-5601. 10.4049/jimmunol.1501929
14. Jordan SC, Legendre C, Desai NM, et al. Imlifidase desensitization in crossmatch-positive, highly-sensitized kidney transplant recipients: results of an international phase 2 trial (Highdes). Transplantation. 2021;105(8):1808-1817. 10.1097/TP.0000000000003496
15. Kjellman C, Maldonado AQ, Sjoholm K, et al. Outcomes at 3 years post-transplant in imlifidase-desensitized kidney transplant patients. Am J Transplant. 2021. https://doi.org/10.1111/ajt.1675...- ouverture dans une nouvelle fenêtre. Online ahead of print.
16. Maldonado AQ, Sundberg A & Runstrom A et al. Patterns of IgG rebound after imlifidase treatment. In: Abstracts of the 2021 Congress of the European Society for Organ Transplantation; August 29-September 1, 2021; Milan, Italy. Abstract POS126.
17. Soveri I, Molne J, Uhlin F, et al. The IgG-degrading enzyme of Streptococcus pyogenes causes rapid clearance of anti-glomerular basement membrane antibodies in patients with refractory anti-glomerular basement membrane disease. Kidney Int. 2019;96:1234-1238. 10.1016/j.kint.2019.06.019
18. Runstrom A, Sundberg A & Stenberg Y et al. Rabbit anti-thymocyte globulin as induction therapy following desensitization with imlifidase. In: Abstracts of the 2021 Congress of the European Society fo Organ Transplantation; August 29-September 1, 2021; Milan, Italy. Abstract OP513.
19. Jordan SC, Kucher K, Bagger M, et al. Intravenous immunoglobulin significantly reduces exposure of concomitantly administered anti-C5 monoclonal antibody tesidolumab. Am J Transplant. 2020;20:2581-2588. 10.1111/ajt.15922
|
Language: | English.
|
Document Type: | MINIREVIEW.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 1600-6135
|
NLM Journal Code: | 100968638
|
DOI Number: | https://dx.doi.org/10.1111/ajt.1...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|